{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Coates MM"],"funding":["American Heart Association","Leona M. and Harry B. Helmsley Charitable Trust","Wound Healing Foundation","National Heart, Lung, and Blood Institute","NHLBI NIH HHS","World Heart Federation","National Institutes of Health"],"pagination":["e957-e966"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9087136"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(7)"],"pubmed_abstract":["Background
Despite declines in deaths from rheumatic heart disease (RHD) in Africa over the past 30 years, it remains a major cause of cardiovascular morbidity and mortality on the continent. We present an investment case for interventions to prevent and manage RHD in the African Union (AU).Methods
We created a cohort state-transition model to estimate key outcomes in the disease process, including cases of pharyngitis from group A streptococcus, episodes of acute rheumatic fever (ARF), cases of RHD, heart failure, and deaths. With this model, we estimated the impact of scaling up interventions using estimates of effect sizes from published studies. We estimated the cost to scale up coverage of interventions and summarised the benefits by monetising health gains estimated i"],"journal":["The Lancet. Global health"],"pubmed_title":["An investment case for the prevention and management of rheumatic heart disease in the African Union 2021-30: a modelling study."],"pmcid":["PMC9087136"],"funding_grant_id":["K23 HL140133","1K23HL140133"],"pubmed_authors":["Eisele JL","Watkins DA","Mocumbi AO","Sliwa K","Kwan GF","Coates MM","Klassen SL","Berteletti F","Perel P","Prabhakaran D","Zuhlke L","Habtemariam MK","Bukhman G"],"additional_accession":[]},"is_claimable":false,"name":"An investment case for the prevention and management of rheumatic heart disease in the African Union 2021-30: a modelling study.","description":"Background
Despite declines in deaths from rheumatic heart disease (RHD) in Africa over the past 30 years, it remains a major cause of cardiovascular morbidity and mortality on the continent. We present an investment case for interventions to prevent and manage RHD in the African Union (AU).Methods
We created a cohort state-transition model to estimate key outcomes in the disease process, including cases of pharyngitis from group A streptococcus, episodes of acute rheumatic fever (ARF), cases of RHD, heart failure, and deaths. With this model, we estimated the impact of scaling up interventions using estimates of effect sizes from published studies. We estimated the cost to scale up coverage of interventions and summarised the benefits by monetising health gains estimated i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-06-01T01:33:15.085Z","creation":"2024-11-14T02:03:19.733Z"},"accession":"S-EPMC9087136","cross_references":{"pubmed":["33984296"],"doi":["10.1016/S2214-109X(21)00199-6"]}}